ATE258426T1 - Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen - Google Patents

Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen

Info

Publication number
ATE258426T1
ATE258426T1 AT97940944T AT97940944T ATE258426T1 AT E258426 T1 ATE258426 T1 AT E258426T1 AT 97940944 T AT97940944 T AT 97940944T AT 97940944 T AT97940944 T AT 97940944T AT E258426 T1 ATE258426 T1 AT E258426T1
Authority
AT
Austria
Prior art keywords
compositions
pharmaceutical
methods
topical application
epidermis
Prior art date
Application number
AT97940944T
Other languages
English (en)
Inventor
David W Osborne
Original Assignee
Virotex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virotex Corp filed Critical Virotex Corp
Application granted granted Critical
Publication of ATE258426T1 publication Critical patent/ATE258426T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT97940944T 1996-09-11 1997-09-10 Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen ATE258426T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,454 US5863560A (en) 1996-09-11 1996-09-11 Compositions and methods for topical application of therapeutic agents
PCT/US1997/015919 WO1998010746A1 (en) 1996-09-11 1997-09-10 Compositions and methods for topical application of therapeutic agents

Publications (1)

Publication Number Publication Date
ATE258426T1 true ATE258426T1 (de) 2004-02-15

Family

ID=24862185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940944T ATE258426T1 (de) 1996-09-11 1997-09-10 Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen

Country Status (11)

Country Link
US (3) US5863560A (de)
EP (1) EP0957900B1 (de)
JP (2) JP4276298B2 (de)
AT (1) ATE258426T1 (de)
AU (1) AU737365B2 (de)
CA (1) CA2265461C (de)
DE (1) DE69727398T2 (de)
DK (1) DK0957900T3 (de)
ES (1) ES2212128T3 (de)
PT (1) PT957900E (de)
WO (1) WO1998010746A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157036A1 (en) * 2002-02-20 2003-08-21 Osborne David W. Topical dapsone for the treatment of acne
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
RU2148396C1 (ru) * 1998-08-25 2000-05-10 Пермское научно-производственное объединение "Биомед" Способ определения активного вещества в дифильных мазевых основах
MXPA02007415A (es) * 2000-01-31 2004-09-10 Collaborative Technologies Inc Composiciones topicas libres de tensioctivo y metodos para su preparacion rapida.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020193321A1 (en) * 2000-12-12 2002-12-19 Mohan Vishnupad Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions
US6495596B1 (en) 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6998421B2 (en) 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
US20030144362A1 (en) * 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
AU2003231571A1 (en) * 2002-04-30 2003-11-17 Mochida Pharmaceutical Co., Ltd. External preparation enhanced in systemic property of vidarabine
US20040086469A1 (en) * 2002-10-30 2004-05-06 Osborne David W. Protectant for UV-induced skin damage
US6855341B2 (en) * 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US20080274209A1 (en) * 2002-11-04 2008-11-06 Integritas Pharma, Inc. Methods of treating inflammation
JP4591746B2 (ja) * 2002-12-03 2010-12-01 大正製薬株式会社 難溶性抗ウイルス成分含有水溶性外用剤組成物
WO2004105662A1 (en) * 2003-05-23 2004-12-09 Program For Appropriate Technology In Health Microbicidal compositions and methods of use
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20060229258A1 (en) * 2003-07-30 2006-10-12 Daniela Serikaku Steroidal compositions containing hydroxycarboxylic acids and methods of using the same
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
WO2005016296A1 (en) * 2003-08-13 2005-02-24 Qlt Usa, Inc. Emulsive composition containing dapsone
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
WO2006004759A2 (en) * 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
US20060024372A1 (en) * 2004-07-29 2006-02-02 Utterberg David S High viscosity antibacterials
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
WO2006037047A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
CN101189022B (zh) 2004-10-27 2012-02-29 丹佛大学 促肾上腺皮质激素类似物以及相关方法
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006113796A2 (en) * 2005-04-20 2006-10-26 Xylos Corporation Microbial cellulose materials for use in transdermal drug delivery system
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
WO2007016450A2 (en) * 2005-07-29 2007-02-08 Beth Israel Deaconess Medical Center Methods for treating or preventing reactivation of a latent herpesvirus infection
CA2620903A1 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
ES2399763T3 (es) 2005-10-12 2013-04-03 Unimed Pharmaceuticals, Llc Gel de testosterona mejorado y método de utilización
JP2007320886A (ja) * 2006-05-31 2007-12-13 Isp Japan Kk 含水ゲル状シート剤及びその製造方法
CA2655809C (en) * 2006-07-21 2013-10-01 Bridge Pharma, Inc. Dermal anesthetic compounds
CA2714674A1 (en) 2008-02-27 2009-09-03 John Steven Garrett Dapsone to treat rosacea
US20100029781A1 (en) * 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
EP2899268A1 (de) 2008-10-10 2015-07-29 Lusomedicamenta, S.A. Anitbakterielle Phagenpeptide und Verfahren zur Verwendung davon
CN105456300B (zh) 2009-02-06 2019-07-09 抗菌技术,生物技术研究与发展股份有限公司 抗菌噬菌体、噬菌体肽及其使用方法
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
US8999302B1 (en) 2009-10-22 2015-04-07 Aplicare, Inc. Skin dye protectant formulations
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
PT2616087T (pt) 2010-09-17 2018-12-20 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
WO2012052479A2 (en) 2010-10-21 2012-04-26 Galderma S.A. Brimonidine gel compositions and methods of use
US9034322B2 (en) 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP3192501B1 (de) * 2011-05-25 2020-05-13 Novaliq GmbH Topische pharmazeutische zusammensetzung auf der basis von semifluorierten alkanen
RU2014102494A (ru) * 2011-06-30 2015-08-10 Аллерган, Инк. Ретиноидные композиции местного применения и способы лечения состояний кожи
RU2654596C2 (ru) 2012-03-19 2018-05-21 Текнифар-Индустриа Текника Фармасеутика С.А. Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
MY166228A (en) 2012-09-12 2018-06-22 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
EP4342537A3 (de) 2012-09-12 2024-07-03 Novaliq GmbH Semifluorierte alkanzusammensetzungen
ES2644342T3 (es) 2012-11-20 2017-11-28 Allergan, Inc. Composiciones de dapsona y dapsona/adapaleno tópicas y métodos para el uso de las mismas
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US20160051499A1 (en) 2014-07-31 2016-02-25 Allergan, Inc. Comparative efficacy and tolerability of dapsone 5% in adult versus adolescent females with acne vulgaris
CN113662928A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
AU2016348527A1 (en) * 2015-11-04 2018-05-24 Allergan, Inc. Methods of treatment of acne vulgaris using topical dapsone compositions
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3612228B1 (de) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Jodzusammensetzungen
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
BR112020006072A2 (pt) 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US20210062137A1 (en) 2017-12-22 2021-03-04 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
EP3758676A1 (de) 2018-03-02 2021-01-06 Novaliq GmbH Pharmazeutische zusammensetzungen mit nebivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
MX2020013192A (es) 2018-06-04 2021-08-16 Arcutis Inc Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast.
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
CA3112504A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (de) 2019-02-13 2024-09-25 Novaliq GmbH Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation
EP3937905A4 (de) 2019-03-14 2022-12-28 Crescita Therapeutics Inc. Abspülbare zusammensetzungen und deren verwendungen zur wirkstoffabgabe
US11746352B2 (en) 2019-12-30 2023-09-05 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread
US12098372B2 (en) 2019-12-30 2024-09-24 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread
CA3166300A1 (en) 2020-01-31 2021-08-05 David W. Osborne Topical roflumilast formulation having improved delivery and plasma half-life
US11617773B2 (en) 2020-04-08 2023-04-04 Eligo Bioscience Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
CA3174093A1 (en) 2020-04-08 2021-10-14 Eligo Bioscience Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
EP3922719A1 (de) 2020-06-12 2021-12-15 Eligo Bioscience Spezifische entkolonisierung von antibiotikaresistenten bakterien für prophylaktische zwecke
US20230235361A1 (en) 2020-07-03 2023-07-27 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
WO2022056299A1 (en) 2020-09-11 2022-03-17 Pinnacle Biologics, Inc. Photodynamic therapy compositions and methods of use thereof
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
WO2022144381A1 (en) 2020-12-30 2022-07-07 Eligo Bioscience Microbiome modulation of a host by delivery of dna payloads with minimized spread
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2023057598A1 (en) 2021-10-07 2023-04-13 Eligo Bioscience Methods involving bacterial strain replacement
WO2023057599A1 (en) 2021-10-07 2023-04-13 Eligo Bioscience Methods involving bacteroides strain replacement
AU2022429340A1 (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
CN120166935A (zh) 2022-09-15 2025-06-17 阿尔库缇斯生物疗法股份有限公司 罗氟司特和能够溶解大量该药物的溶剂的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US4731359A (en) * 1980-04-21 1988-03-15 University Of Southern California Prolonged action drug formulation
US4507287A (en) * 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
US4853439A (en) * 1987-10-09 1989-08-01 Gaf Corporation Water-soluble complexes of water-insoluble organic compounds
US5180576A (en) * 1991-08-30 1993-01-19 Church & Dwight Co., Inc. Anticalculus dentifrices
GB2260080A (en) * 1991-10-04 1993-04-07 Rhone Poulenc Rorer Ltd Gelled alginate compositions
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9408545D0 (en) * 1994-04-29 1994-06-22 Zyma Sa Compositions
CN1157563A (zh) * 1994-09-06 1997-08-20 日本化药株式会社 软膏剂
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents

Also Published As

Publication number Publication date
DK0957900T3 (da) 2004-06-01
EP0957900B1 (de) 2004-01-28
AU737365B2 (en) 2001-08-16
EP0957900A1 (de) 1999-11-24
US6620435B1 (en) 2003-09-16
CA2265461C (en) 2004-11-30
JP2006096774A (ja) 2006-04-13
DE69727398T2 (de) 2004-11-25
JP4276298B2 (ja) 2009-06-10
WO1998010746A1 (en) 1998-03-19
JP2001500863A (ja) 2001-01-23
PT957900E (pt) 2004-06-30
CA2265461A1 (en) 1998-03-19
ES2212128T3 (es) 2004-07-16
US5863560A (en) 1999-01-26
US6060085A (en) 2000-05-09
DE69727398D1 (de) 2004-03-04
AU4261097A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
ATE258426T1 (de) Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen
CA2468539C (en) Delivery of medicaments to the nail
AU747041B2 (en) Penetration enhancing and irritation reducing systems
US6231875B1 (en) Acidified composition for topical treatment of nail and skin conditions
WO2004078122A3 (en) Invisible patch for active agnet controlled delivery
JPS5815910A (ja) 生物影響剤の皮膚浸透を高めるためのユ−カリプト−ル使用
JP2003514875A (ja) 創傷治癒を改善し、薬を投与するためのプロペラント不要のスプレー式皮膚パッチ組成物
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
JP2003514835A (ja) 瘢痕を治療する方法と組成物
EP0857488A1 (de) Verfahren und Zusammensetzungen zur Erhöhung des Hautdurchtritts von Arzneistoffen unter Verwendung von Permeationsbeschleunigern
EP0247142A1 (de) Filmbildende arzneimittelträger zur verabreichung von arzneimitteln an nägeln; verfahren zur verwendung.
WO2007120868A2 (en) Bioavailability enhancement of lipophilic drug by use solvent system
WO1999026589A3 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
JPH02207024A (ja) 経皮吸収製剤
AU5190790A (en) Percutaneous drug delivery system
IE51016B1 (en) Composition of matter for topical application comprising a bio-affecting agent and n,n-diethyl-m-toluamide
US20100098732A1 (en) Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss
EP0748216A1 (de) Systemischer wirkstoffverabreichungssystem durch anwendung auf den nageln
JPS63208537A (ja) 経皮吸収促進剤及びこれを含有する皮膚外用製剤
Hollingsbee et al. The effect of a hydrocolloid dermatological patch (Actiderm) in potentiating the skin blanching activity of triamcinolone acetonide
Lee et al. New Developments in Topical Psoriasis Therapy
AU2006247934A1 (en) Low dose administration of a topical composition
AU2003246031A8 (en) An acidified composition for topical treatment of nail and skin conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0957900

Country of ref document: EP